Our novel study highlights the synergistic therapeutic potential of the novel combination of Abe, a CDK4/6 inhibitor, and Pan, an HDACi when tested in vitro in highly aggressive pancreatic cancer cells. Here, CDK4 is linked to familial pancreatic carcinoma.